Development of Advanced Genomic Characterization Technologies (STTR [R41/R42])
The summary for the Development of Advanced Genomic Characterization Technologies (STTR [R41/R42]) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Development of Advanced Genomic Characterization Technologies (STTR [R41/R42]): -The National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) solicit applications for research projects to develop highly innovative and novel genomic analysis technologies to provide new insights and understanding into the role of genetic alterations in cancer. This Funding Opportunity Announcement (FOA) is a component of The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov) Pilot Project recently announced by the NCI and the NHGRI. The overall aim of The Cancer Genome Atlas initiative is to accelerate the understanding of the molecular basis of cancer through the development and application of high resolution, high throughput genome analysis technologies in the study of human cancer. In addition, the TCGA Pilot Project is designed to assess the technical feasibility and clinical relevance of conducting a comprehensive analysis of genomic alterations found in human cancers. -In this FOA, the term technology denotes methods and tools that enable research including, but not limited to, instrumentation, techniques, and devices for use in basic and translational cancer research. Genomic analysis technologies are distinct from databases, individual reagents and collections of reagents, therapeutic agents, and tissue repositories, which are supported through other initiatives. -The purpose of this FOA is to develop new and improved high resolution, high-throughput technologies to detect alterations in the cancer genome, epigenome, or transcriptome, including, but not limited to: DNA segment copy number, translocations, loss of heterozygosity and epigenomic modifications, and gene expression profiling. Included are significant improvements in sensitivity such that reliable, whole-genome data are generated from 1,000 or fewer cells and from samples that are flash frozen, embedded and frozen in a cryopreservation medium, such as optimal cutting temperature (OCT) compound. The proposed projects should maximize genome coverage and resolution to provide a complete and comprehensive analysis of the cancer genome, epigenome, and/or transcriptome.
|Federal Grant Title:||Development of Advanced Genomic Characterization Technologies (STTR [R41/R42])|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Health Education|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-CA-07-030|
|Type of Funding:||Grant|
|CFDA Descriptions:||Cancer Construction 93.393 Cancer Cause and Prevention Research|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Aug 25, 2006|
|Posted Date:||Jun 14, 2006|
|Creation Date:||Jun 14, 2006|
|Archive Date:||Sep 24, 2006|
|Total Program Funding:||$1,000,000|
|Maximum Federal Grant Award:||$850,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:||5|
|Cost Sharing or Matching:||93.394 -- Cancer Detection and Diagnosis Research|
- Applicants Eligible for this Grant
- Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Foreign institutions are not eligible to apply. In STTR Phase I and Phase II, at least 40% of the work must be performed by the small business concern and at least 30% of the work must be performed by the single, partnering research institution. The basis for determining the percentage of work to be performed by each of the cooperative parties will be the total of direct and F and A/indirect costs attributable to each party, unless otherwise described and justified in Item 12, Consortium/Contractual Arrangements, of the PHS398 Research Plan component of the SF424 (R and R) application forms. The NIH will accept as many "different" applications as the applicant organization chooses. However, the NIH will not accept similar grant applications with essentially the same research focus from the same applicant organization. This includes derivative or multiple applications that propose to develop a single product, process or service that, with non-substantive modifications, can be applied to a variety of purposes. Applicants may not simultaneously submit identical/essentially identical applications under both this funding opportunity and another HHS FOA, including the current SBIR or STTR Parent FOAs.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...